Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:16:20.299Z.
Calculation as of: 2026-10-06T14:16:20.299Z.
Quote observation: 2026-10-06T14:14:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80308b770ced1bdfd1e00e86669fc95a739831df2c659c0b91f47c7a41a76c0c
PE RATIO
N/A
Market Cap
$170.58M
PE Ratio
N/A
TTM Avg
11.57
3Y Avg
11.57
5Y Avg
11.57
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | $175.98M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $173.51M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.23M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $170.58M | N/A | 11.57 | 11.57 | 11.57 |
| MediWound Ltd. (MDWD)vs › | $172.45M | N/A | 7.76 | 7.76 | 7.76 |
| Journey Medical Corporation (DERM)vs › | $181.64M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A | 5.36 | 5.36 | 8.25 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.07M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.88M | N/A | 65.68 | 52.50 | 80.75 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $191.04M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$24.23
Forward EPS (Est.)
$-25.01
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
